Floatz logo

Belzutifan

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

426 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Degarelix
Bayer
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB
Flotufolastat F-18
Washington University School of Medicine
Phase 4BB
Estramustine
The University of Texas Health Science Center, Houston
Phase 3BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Belzutifan is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Von Hippel Lindau DiseaseDormant
BB
Indicative ·
66 / 100
View asset →
von Hippel-Lindau diseaseDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →